# IMUX catalysts: IMMUNIC, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/imux/catalysts

> IMMUNIC, INC. (IMUX) has 3 upcoming catalysts. The next is the imu-838 tablets topline data readout, Dec 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | IMMUNIC, INC. |
| Ticker | IMUX (Nasdaq) |
| SEC CIK | 1280776 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/imux |

## Cash runway

Cash $132.0M as of 2026-09-30; quarterly burn $28.4M; about 13.9 months of runway at that rate (XBRL company facts, accession 0001280776-26-000021).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 9, 2023 | [Vidofludimus interim data readout](https://sec-api.dev/pdufa/vidofludimus) | IMUX |  | completed, positive | "Our Phase 2 CALLIPER trial of vidofludimus calcium in PMS was designed to corroborate vidofludimus calcium's neuroprotective potential and to evaluate the clinical efficacy, safety and tolerability of vidofludimus calcium in a broad set of PMS patients to determine the suitability of advancing to a confirmatory Phase 3 program, On October 9, 2023, we announced positive interim data from the CALLIPER trial, showing biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1280776/000128077625000008/vtl-20250331.htm)) |
| October 22, 2024 | [IMMUNIC, INC. interim data readout](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | completed, positive | "On October 22, 2024, we announced a positive outcome of an interim analysis of the ENSURE program, with an unblinded Independent Data Monitoring Committee ("IDMC") confirming that the predetermined futility criteria have not been met and recommending that both ENSURE trials should continue without changes, including no need for a potential increase of the sample size." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1280776/000128077625000017/vtl-20250930.htm)) |
| October 22, 2024 | [Vidofludimus interim data readout](https://sec-api.dev/pdufa/vidofludimus) | IMUX |  | completed, positive | "On October 22, 2024, we announced a positive outcome of an interim analysis of the ENSURE program, with an unblinded Independent Data Monitoring Committee ("IDMC") confirming that the predetermined futility criteria have not been met and recommending that both ENSURE trials should continue without changes, including no need for a potential increase of the sample size." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1280776/000128077625000012/vtl-20250630.htm)) |
| October 22, 2024 | [IMMUNIC, INC. interim data readout](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | completed, positive | "On October 22, 2024, we announced a positive outcome of an interim analysis of our Phase 3 ENSURE program." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/imux-20251231.htm)) |
| Apr 2025 | [Imu-838 tablets topline data readout](https://sec-api.dev/pdufa/imu-838) | IMUX |  | scheduled | "Top-line data from the CALLIPER trial, for which the recruitment of 467 total patients was completed in August 2023, is expected to be available in April 2025." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1280776/000119380525000455/e664312_424b5-immunic.htm)) |
| Apr 2025 | [IMMUNIC, INC. topline data readout](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | scheduled | "Top-line data from the CALLIPER trial, for which the recruitment of in total 467 patients was completed in August 2023, is expected to be available in April 2025." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1280776/000119380525000455/e664312_424b5-immunic.htm)) |
| Apr 2025 | [Vidofludimus topline data readout](https://sec-api.dev/pdufa/vidofludimus) | IMUX |  | scheduled | "◦release by the Company of topline data from its Phase 2b clinical trial of vidofludimus calcium (IMU-838) in progressive multiple sclerosis, which data is currently expected in or around April 2025;" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1280776/000128077625000005/imux-20241231.htm)) |
| June 5, 2025 | [Vidofludimus topline data readout](https://sec-api.dev/pdufa/vidofludimus) | IMUX |  | completed, positive | "On June 5, 2025, we announced additional data from our Phase 2 CALLIPER trial in PMS, further supporting the positive top-line results announced on April 30, 2025, and underlining vidofludimus calcium's neuroprotective potential." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1280776/000128077625000012/vtl-20250630.htm)) |
| August 7, 2025 | [IMMUNIC, INC. earnings report](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | completed | "IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the second quarter and six months ended June 30, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000119380525001164/e664768_ex99-1.htm)) |
| late 2025 | [Vidofludimus topline data readout](https://sec-api.dev/pdufa/vidofludimus) | IMUX |  | scheduled | "Top-Line Data from Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000119380525001570/e664954_ex99-1.htm)) |
| November 13, 2025 | [IMMUNIC, INC. earnings report](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | completed | "IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results for the three and nine months ended September 30, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000119380525001570/e664954_ex99-1.htm)) |
| February 26, 2026 | [IMMUNIC, INC. earnings report](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | completed | "IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results for the year ended December 31, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000181/e665186_ex99-1.htm)) |
| May 13, 2026 | [IMMUNIC, INC. earnings report](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | completed | "IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000593/e665461_ex99-1.htm)) |
| August 6, 2026 | [IMMUNIC, INC. earnings report](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | completed | "IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000119380526001071/e665684_ex99-2.htm)) |
| late 2026 | [Vidofludimus trial start](https://sec-api.dev/pdufa/vidofludimus) | IMUX |  | scheduled | "Initiation of a Phase 3 clinical trial of vidofludimus calcium in progressive MS is expected later in 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1280776/000128077626000018/vtl-20260630.htm)) |
| late 2026 | [Vidofludimus topline data readout](https://sec-api.dev/pdufa/vidofludimus) | IMUX |  | scheduled | "Our most advanced product candidate, vidofludimus calcium, had the first patient enrolled in a Phase 3 program for relapsing multiple sclerosis ("RMS") in November 2021 and we do not expect the readout of topline data from this trial until the end of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/imux-20251231.htm)) |
| November 2026 | [Imu-838 tablets primary completion](https://sec-api.dev/pdufa/imu-838) | IMUX | Multiple Sclerosis | scheduled | "NCT05134441 (Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Immunic AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05134441)) |
| November 2026 | [Imu-838 tablets primary completion](https://sec-api.dev/pdufa/imu-838) | IMUX | Multiple Sclerosis, Relapsing-Remitting | scheduled | "NCT05201638 (Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Immunic AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05201638)) |
| November 13, 2026 | [IMMUNIC, INC. earnings report](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | completed | "Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000149315226051543/ex99-1.htm)) |
| Dec 2026 | [Imu-838 tablets topline data readout](https://sec-api.dev/pdufa/imu-838) | IMUX | relapsing multiple sclerosis | scheduled | "The company's lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available in December 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000149315226051543/ex99-1.htm)) |
| 1H 2027 | [Imu-838 tablets trial start](https://sec-api.dev/pdufa/imu-838) | IMUX |  | scheduled | "Initiation of an additional Phase 3 clinical trial in progressive multiple sclerosis is ongoing, with first-patient-enrolled expected in the first half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000149315226051543/ex99-1.htm)) |
| February 17, 2031 | [IMMUNIC, INC. topline data readout](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | scheduled | "These warrants will expire upon the earlier of (a) 30 days after the public announcement of topline data from the phase 3 ENSURE trials or (b) February 17, 2031." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/e665154_ex99-1.htm)) |

## Drugs

- [Imu-838 tablets](https://sec-api.dev/pdufa/imu-838): relapsing multiple sclerosis, relapsing multiple sclerosis, with top-line data, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
- [Vidofludimus](https://sec-api.dev/pdufa/vidofludimus): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/imux/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IMUX catalysts: IMMUNIC, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/imux/catalysts

```bibtex
@misc{secapidev_companies_imux_catalysts_20261116,
  title        = {IMUX catalysts: IMMUNIC, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/imux/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_imux_catalysts_20261116","title":"IMUX catalysts: IMMUNIC, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/imux/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
